Translational advancement of immunotherapeutics against pediatric central nervous system tumors.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology or original human data
PubMed 41198341 · doi:10.1016/bs.acr.2025.08.003
What was done
This is a narrative review summarizing the translational state and ongoing clinical trials of immunotherapies for pediatric central nervous system (CNS) tumors. The authors survey four main treatment modalities: cellular therapy, immune checkpoint inhibition, cancer vaccines, and oncolytic viral therapy.
What was found
The abstract reports no numerical data, effect sizes, or trial statistics. It qualitatively notes that immunotherapy for pediatric CNS tumors is in its early stages, with active translation from preclinical pipelines into emerging clinical trials.
Why it matters
High-grade pediatric CNS tumors frequently relapse after standard cytotoxic therapy and leave survivors with severe lifelong morbidity. This review outlines early translational efforts to develop more targeted, less toxic immunotherapeutic options.
Limits
The paper is a narrative review that provides no new empirical data or systematic synthesis. The abstract lacks specific trial identifiers, sample sizes, or quantitative outcome measures. Most discussed approaches remain in early-phase clinical testing or preclinical development.